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Abstract
Objective: Sentinel lymph node biopsy is the standard of care in clinically negative axilla in breast cancer patients for 
which frozen section (FS) is routinely performed intraoperatively. The objective of this study was to justify the use of 
FS in terms of number of tests performed and their impact on decision-making and cost saving.
Materials and Methods: We retrospectively reviewed our prospectively maintained data from January 2014 to 
January 2018 for intraoperative FS in upfront breast conservation surgery patients.
Results: A total of 357 patients were studied. All were female. Median age was 50 years (24–84). Mean tumour size 
was 29.11 mm. Numbers of sentinel lymph nodes identified were 1 in 50 (14.2%) patients, 2 in 121 (33.89%) patients 
and ≥3 in 186 (52%) patients. Number of positive sentinel lymph nodes was 0 in 264 (73.9%) patients, 1 in 62 (17.4%) 
patients, 2 in 20 (5.6%) patients and ≥3 in 11 (3.08%) patients. Axillary lymph node dissection (ALND) was offered 
to 30 (8.4%) patients as per the American College of Surgeons Oncology Group Z0011. The results for ALND showed 
that only 8 (2.3%) out of 30 patients had positive nodes identified in the additional axillary nodes dissected. Sensitivity 
of FS was 97% and specificity was 98.86%. False-negative rate was 3.22%.
Conclusion: Intraoperative FS can be safely omitted in early breast cancer patients undergoing upfront breast 
conservation cancer surgery due to high sensitivity and specificity leading to low false-negative rates. ALND can be 
performed as a second operation as warranted only in a minority of patients.
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Introduction
Lymph node status is one of the most important predictors 
of survival and recurrence in breast cancer. Axillary 
lymph node dissection (ALND) has been a major part of 
breast cancer treatment since the very beginning when 
William S Halsted, a young surgeon at John Hopkins, 
first introduced radical mastectomy in 1882.[1] It involved 
the removal of entire breast, surrounding tissues, pectoral 
muscles and axillary lymph nodes. He hypothesised that 
breast cancer spreads in an orderly fashion and spreads 
locally first followed by axillary lymph nodes and then to 
other organs of the body. Later came the era of modified 
radical mastectomy in 1970s when results of NSABP-04 
trial results were published. It supported the paradigm 
shift to less radical surgery for breast cancer.[2] To further 
minimise the extent of surgery NSABP-06, a randomised 
controlled trial comparing lumpectomy and ALND with 
or without breast irradiation with total mastectomy and 
ALND (modified radical mastectomy) in patients with 
tumours 4 cm or less was conducted.[3] The NSABP B-06 
trial established the concept of breast-conserving surgery 
and confirmed the importance of radiation as a component 
of such treatment.
ALND is associated with high morbidity due to 
complications such as lymphoedema, pain, paraesthesia 
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and shoulder movement restriction. Sentinel lymph node 
biopsy (SLNbx) was first reported in 1994.[4] Compared 
to ALND, SLNbx is associated with less morbidity 
and complications such as impaired shoulder function, 
paraesthesia and lymphoedema.[5,6]
In early 2000 NSABP B-32, a randomised controlled trial 
enrolled 5611 patients and randomised them to undergo 
SLNbx and ALND (Group 1) or SLNbx with ALND only 
if the sentinel lymph node was positive. It concluded that 
sentinel lymph node dissection is enough for patients 
whose sentinel nodes are negative and that there is no 
need to proceed to complete axillary dissection.[7] In 
1999, the American College of Surgeons Oncology Group 
(ACOSOG) launched the Z0011 trial that randomised 
early stage (T1-2, clinically N0) breast cancer patients 
with a tumour-positive sentinel node to completion ALND 
versus observation.[8] It was concluded that patients having 
1–2 positive lymph nodes followed by radiotherapy can 
be omitted from undergoing ALND. However, patients 
with 3 or more positive nodes need to undergo complete 
axillary dissection.
In early breast cancer, an intraoperative frozen section 
(FS) of sentinel lymph nodes is performed routinely to 
assess their status and perform ALND if metastasis found 
avoiding the second operation. The sensitivity of FS ranges 
from 58% to 76% depending on tumour characteristics 
and method of pathological examination.[9-12] It provides 
result within an average time of 20–30 min. However, its 
use has become controversial in early breast cancer due 
to extra cost, increased time and possible false-negative 
rates. In addition, landmark trials like ACOSOG Z0011[13] 
have further questioned the benefit of ALND in cases of 1 
or 2 positive sentinel lymph nodes, making management 
decisions more controversial which should be more 
appropriately made in a multidisciplinary meeting rather 
than on intraoperative assessment.
The aim of this study was to justify the use of intraoperative 
FS in upfront breast conservation cancer surgery in this 
era of controversy with regard to false-negative rates, 
sensitivity and specificity to assess its accuracy in our 
hospital and also to justify the use of FS in terms of number 
of tests performed and their impact on decision-making 
and cost saving.
Materials and Methods
An institutional prospectively maintained database was 
utilised at Shaukat Khanum Memorial Cancer Hospital 
and Research Centre, Pakistan, to retrospectively review 
patients from January 2014 to January 2018 after taking 
Institutional Review Board approval. All the patients with 
invasive tumour requiring breast conservation surgery and 
SLNbx for T1–T2 tumours with clinically negative axilla 
which includes patients with no suspicious nodes on clinical 
examination as well as on radiological investigations 
were included in the study. Patients with ductal carcinoma 
in situ were excluded from the study. Prior neoadjuvant 
chemotherapy patients were also excluded, so only upfront 
surgery patients were reviewed. ACOSOG Z0011 trial 
criterion[10] was applied on all patients as our standard 
hospital guidelines. As per the criteria, only patients with 
tumours <5 cm and no clinically palpable lymph nodes 
underwent upfront surgery with a SLNbx. Patients with 
single positive node were spared of ALND while ALND 
was performed in 3 or more positive lymph nodes according 
to the Z-11 criteria.[10] However, in patients with 2 positive 
lymph nodes, ALND was omitted if tumour was of good 
tumour biology, i.e., oestrogen receptor/progesterone 
receptor (ER/PR) positive and Her2Neu negative.
Sentinel lymph nodes were identified by injecting 
Tc-99m human serum albumin (HSA) a day before 
surgery. A dose of 40 MBq was injected at periareolar 
location. Lymphoscintigraphy was performed at 30 min 
after injection. In case of non-visualization of sentinel 
lymph node on planar scintigraphy, further delayed planar 
and/or SPECT/CT (single photon emission comupted 
tomography/computed tomography) images were 
performed. A gamma probe was used for sentinel lymph 
node localisation. Blue dye (blue patente V Guerbet 2.5%) 
was used in addition to Tc-99m HSA in some patients at the 
time of surgery where there was no localisation of sentinel 
lymph nodes by Tc-99m HSA. 2 ml of blue dye was injected 
subcutaneously at periareolar location. Lymph nodes which 
were suspicious on palpation were also sent for FS.
Sentinel lymph nodes were sent for FS in all patients 
immediately. After lymph nodes were received in pathology 
department, they were cut according to the standard sentinel 
protocol. Tissue was then placed on a metal disc which 
was frozen rapidly to about −20–−30°C by embedding in 
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optimal temperature cutting compound. The tissue was then 
placed in a cryostat, where 1 mm sections were taken using 
a microtome. The sections were placed on glass slides and 
stained with haematoxylin and eosin. The slides were then 
reviewed by two experienced pathologists who then inform 
the referring surgeon about the diagnosis. FS and definitive 
section results were compared regarding the pathological 
diagnosis for the SLNs.
Patient age, body mass index (BMI), side of tumour, tumour 
size, histological tumour type, grade, ER/PR and HER2Neu 
status, duration of surgery and hospital stay were also 
recorded. Size of lymph node metastasis if any was also 
recorded both intraoperatively as reported by pathologist on 
FS and on final histopathology report and the results were 
compared. <2 mm was taken as micrometastases, more 
than 2 mm as macrometastases and isolated tumour cells 
as single tumour cells or cluster of cells less than 0.2 mm.
Data were entered in SPSS version 20 and analysed through 
its statistical programme. False-negative cases were defined 
as patients in whom FS at the time of surgery was reported 
as negative but was found to be positive on final pathology.
Results
A total of 357 patients were studied. All were female. 
Median age was 50 years (24–84). Median BMI was 
30 kg/m2 (16–59). 197 (55.18%) patients had left-sided 
tumour while 160 (44.81%) had right-sided tumour. Average 
tumour size was 29.11 mm. Predominant histological type 
was invasive ductal carcinoma in 344 (96.35%) patients 
while 13 (3.65%) patients had invasive lobular carcinoma. 
172 (48.17%) patients had Grade III tumour, 175 (49%) had 
Grade II, whereas 10 (2.8%) patients had Grade I tumour. 
257 (72%) patients were ER positive, 214 (59.9%) were 
PR positive and only 56 (15.7%) patients were Her2Neu 
positive. Mean operative time was 70 min while mean 
hospital stay was 1 day (0–4) [Table 1].
Median numbers of sentinel lymph nodes identified were 
1 in 50 (14.2%) patients, 2 in 121 (33.89%) patients 
and ≥3 in 186 (52%) patients. All patients had sentinel 
node identified through either blue dye or Tc-99m. 
Median number of positive sentinel lymph nodes was 0 
in 264 (73.9%) patients, 1 in 62 (17.4%) patients, 2 in 
20 (5.6%) patients and ≥3 in 11 (3.08%) patients. ALND 
was offered to 30 (8.4%) patients [Table 2]. All the patients 
with 3 or more positive lymph nodes 11/11 (100%) were 
offered ALND following ACOSOG Z0011 criteria. 
7 patients had 2 lymph nodes positive and 12 patients had 
only 1 lymph node positive, but ALND was performed 
due to larger metastatic deposit, visible metastatic disease 
or larger breast tumour size with poor tumour biology. 
The results for ALND showed that only 8 (2.3%) out 
of 30 patients who had positive nodes identified in the 
Table 1: Patients characteristics
Characteristics Data (n 357)
Age (years): Median (range) 50 (24–84)
Dominant side (Left) 197
Median BMI (range) 30 (16–59)





Invasive ductal Ca 344






















BMI: Body mass index, SLNbx: Sentinel lymph node biopsy, 
SLNs: Sentinel lymph node, ER: Oestrogen receptor, PR: Progester-
one receptor
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additional axillary nodes dissected. So out of a total of 
357 patients, only 30 (8.4%) patients needed an ALND 
out of which only 8 (2.3%) patients had disease beyond 
the identified sentinel node which included most of those 
patients who had 3 positive lymph nodes on FS. Hospital 
stay was increased by an average of 1 day in case of 
ALND.
FS reports of sentinel lymph nodes were compared 
to final histopathology [Table 3]. True-positive nodes 
were found in 90 (25.21%) patients and true negatives 
were identified in 261 (73.1%) patients. Only 3 (0.8%) 
patients had false-negative reports along with 3 (0.8%) 
other having false-positive reports. None of the false-
negative patients required ALND as only 1 lymph node 
was positive, and ALND would have been avoided even if 
they were positive on intraoperative FS. Likewise, false-
positive patients also had only 1 lymph node positive on 
intraoperative FS so ALND was avoided.
FS reports were also evaluated according to molecular 
subtypes to assess which tumour biology is more likely 
to have positive lymph nodes. 39 patients with single 
positive lymph nodes, 15 with 2 positive lymph nodes 
and 10 with 3 or more positive lymph nodes were of 
luminal A type (ER+ve, PR+ve and Her2Neu−ve). 7 patients 
with single positive lymph nodes, 3 with 2 positive lymph 
nodes and 1 with 3 or more positive lymph nodes were of 
luminal B type (ER+ve, PR−ve and Her2Neu+ve). 14 patients 
with single positive lymph nodes, 1 with 2 positive lymph 
nodes and none with 3 or more positive lymph nodes were 
of triple-negative breast cancer (TNBC) type (ER−ve, PR−ve 
and Her2Neu−ve). 2 patients with single positive lymph 
nodes, 1 with 2 positive lymph nodes and none with 3 or 
Table 2: Number of positive (Macromets) LNs identified at SLNBx
Number of lymph nodes Frequency Percentage Cumulative percent
0 264 73.9 73.9
1 62 17.4 91.3
2 20 5.6 96.9
3 10 2.8 99.7
6 1 0.3 100
Total 357
SLNBx: Sentinel lymph node biopsy, LN: Lymph node
Table 3: Comparison of frozen section and final histopathology
Parameters Frozen section Final histopathology Frequency Percentage
TP Positive Positive 90 25.21
TN Negative Negative 261 73.10
FN Negative Positive 3 0.80
FP Positive Negative 3 0.80
TP: True positive, TN: True negative, FN: False negative, FP: False positive
Table 4: Intraoperative frozen section report according to luminal type
Molecular sutype Negative 1 LN+ve 2 LNs+ve 3 or more LNs+ve Total
Luminal A 125 39 15 10 189
Luminal B 57 7 3 1 68
TNBC 65 14 1 0 80
Her2 Enriched 16 2 1 0 19
Total 263 62 20 11 356
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more positive lymph nodes were Her2 enriched (ER−ve, 
PR−ve and Her2Neu+ve) [Table 4].
Sensitivity of FS in our hospital was 97% while specificity 
of 98.86%. False-negative rates were calculated to be 
3.22%. Positive predictive value was 96.77% and negative 
predictive value was 98.86% [Table 5].
Discussion
SLNbx is the current standard for all patients with early 
breast cancer undergoing upfront surgery. All nodes 
retrieved are sent for FS and those patients with 3 or more 
positive nodes undergo axillary dissection. Our study has 
shown that the number of patients requiring an ALND 
after SLNBx is very low. Only 30 out of 357 patients 
needed an axillary dissection. For identifying one patient 
who merits an axillary dissection, a total of 12 FS s were 
performed.
It is important to discuss that 264 patients had a negative 
axilla and required no ALND. 73 patients who had a 
positive SLNBx did not require ALND. That means that 
for 327 patients the SLNB had no role in decision-making 
regarding axillary dissection. Keeping this in mind, we 
can say that a FS has a limited role in decision-making 
after SLNBx in early breast cancer. For this reason, a lot 
of studies have questioned the role of a routine FS for 
SLNBx in early breast cancer.[14,15]
Rónká et al. in a prospective trial showed that, with respect 
to hospital costs, FS analysis seems to be worthwhile as 
long as the false-negative rate does not exceed 35%.[16] The 
false-negative rate in our study was 3.22% which meets 
international standards. The reported rates are between 
2.8% and 4.9% [Table 3].[17,18]
Julie Anne Bishop in her study showed that since the 
Z0011, intraoperative sentinel lymph node evaluation has 
significantly decreased as only 3% of patients underwent 
ALND and 97% (147 of 151) of the patients were spared 
ALND. Therefore, routine FS diagnosis for sentinel lymph 
node biopsies can be avoided in these patients.[14]
Leonardo Russo in a retrospective analysis of 281 patients 
showed that comprehensive information of the definitive 
histopathological findings either of the primary tumour 
and SLNs may help in making a better decision to 
completion ALND without an intraoperative FS analysis. 
The false-negative rate in SLN with macrometastasis 
was 13.1% and for micrometastasis cases was 66.7% 
(P < 0.001).[19]
Another aspect of omitting a FS is cost saving. Our current 
practice is to perform FS intraoperatively in all early breast 
cancer patients with clinically negative axilla to confirm 
axillary metastasis and avoid unnecessary ALND.
The cost of one FS in Pakistan is 95 USD and it requires 
minimum of 20–30 min for processing by pathology 
department. As reported in our study out of 357 patients 
only 30 patients required ALND. For identifying one 
patient who merits an axillary dissection, a total of 
12 FSs were offered which increases the cost to 1140 USD. 
If we omit this FS, we can save considerable cost and 
time. Cost is increased further in the form of manpower 
as substantial amount of work is required by laboratory 
technicians and pathologists. In addition, longer operation 
room time utilisation as the length of procedure may be 
increased further on the result of FS and sometimes due 
to increased waiting time leading to delay of surgeries and 
even cancellations. However, doing a second operation 
can have emotional impact on patient along with cost 
and morbidity.
In our study an interesting fact was that out of 11 patients 
who had 3 or more positive lymph nodes, 10 were of 
luminal A type and only 1 was of luminal B type. Although 
triple-negative breast cancer patients and Her2-enriched 
type are considered to be more aggressive, this could be 
due to the small number of triple-negative breast cancer 
Table 5: Sensitivity and specificity of frozen section
Parameter Calculations Value (%)
Sensitivity TP/TP+FN 97
Specificity TN/TN+FP 98.86




PPV: Positive predictive value, NPV: Negative predictive value, 
TP: True positive, TN: True negative, FN: False negative, FP: False 
positive
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patients in the study group. Further studies need to be 
conducted to confirm these findings in case of axillary 
metastasis.
Conclusion
Intraoperative FS can be safely omitted in early breast 
cancer patients undergoing upfront breast conservation 
cancer surgery. ALND can be performed as a second 
operation if required post-chemotherapy as the percentage 
of such patients is very small. Although difficult to define 
a specific group, FS can be performed in selected group 
of patients with clinically suspicious looking nodes, large 
primary tumour size and poor tumour biology.
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